Protalix Biotherapeutics, Inc. (PLX) Release: UPLYSO™ (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
4/29/2013 11:40:57 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease
4/2/2013 11:39:12 AM
More...
|
Pfizer Inc. (PFE), Protalix Biotherapeutics, Inc. (PLX) Type I Gaucher Disease Drug Uplyso Gets Brazilian Approval
3/19/2013 7:06:08 AM
More...
|
Is Pfizer Inc. (PFE)'s Collaborator Protalix Biotherapeutics, Inc. (PLX) Preparing for a Possible $1 Billion Sale?
2/6/2013 7:39:36 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102
12/10/2012 9:10:55 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Signs $8.3 Million Deal With Pfizer Inc. (PFE) to Continue Managing Elelyso Trials
12/6/2012 7:14:17 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) to Present at the 2012 Jefferies and Co. Global Healthcare Conference in London
11/8/2012 9:28:20 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Receives Marketing Authorization for Elelyso™ for the Treatment of Gaucher Disease From the Israeli Ministry of Health
9/27/2012 10:02:58 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) to Present at the UBS Global Life Sciences Conference
9/12/2012 10:02:26 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Modified Enzyme Replacement Therapy
8/13/2012 9:08:37 AM
More...
|
|